IMMUNOHISTOCHEMISTRY OF THE ANDROGEN RECEPTOR IN HUMAN BENIGN AND MALIGNANT PROSTATE TISSUE
IMMUNOHISTOCHEMISTRY OF THE ANDROGEN RECEPTOR IN HUMAN BENIGN AND MALIGNANT PROSTATE TISSUE
复制标题
DOI：
10.1016/s0022-5347(17)36284-5
复制
发表时间：
1993-05-01
影响因子：
6.6
通讯作者：
MOHLER, JL
中科院分区：
文献类型：
--
作者：
MIYAMOTO, KK;MCSHERRY, SA;MOHLER, JL
雄激素受体在前列腺癌发生发展中的作用尚未明确。雄激素受体抗体的发展为直接免疫组织化学分析提供了新的机会。应用抗生物素蛋白-生物素复合物法，比较了新鲜前列腺癌和良性前列腺增生（BPH）组织雄激素受体的染色特征。从10名前列腺癌患者（68.5 ± 7.3岁标准差）的相同根治性耻骨后前列腺切除术标本中获得的癌症和BPH以及从10名非癌症患者（71.5 ± 7.7岁）获得的BPH与AR 52（一种针对合成雄激素受体肽的兔多克隆抗体）孵育。对每个切片中的细胞核进行雄激素受体染色强度分级（0-不存在，1-弱，2-中等或3-强），并确定在这些强度水平中的每一个下采样的细胞核染色的百分比（0 - 100%）。总强度评分（0 - 300）是每个强度评分（0 - 3）及其相应百分比的乘积的总和。癌切片（166 +/- 69）的染色强度较低，且比癌症患者（246 +/- 41，Student t检验p < 0.05）和非癌患者（225 +/- 39，p < 0.05）的BPH染色更不均匀。前列腺癌组织中雄激素受体染色强度的降低和异质性的增加可能意味着前列腺癌和BPH之间雄激素受体在数量或功能上的差异。
The role of the androgen receptor in the development and progression of prostatic carcinoma has not been defined. The development of androgen receptor antibodies has provided new opportunities for direct immunohistochemical analysis. We compared the androgen receptor staining characteristics of fresh human prostatic carcinoma with benign prostatic hyperplasia (BPH) using an avidin-biotin complex method. Cancer and BPH obtained from the same radical retropubic prostatectomy specimen in 10 prostate cancer patients (68.5 +/- 7.3 years old standard deviation) and BPH from 10 noncancer patients (71.5 +/- 7.7 years old) were incubated with AR52, a rabbit polyclonal antibody against a synthetic androgen receptor peptide. Nuclei within each section were graded for intensity of androgen receptor staining (0-absent, 1-weak, 2-moderate or 3-strong) and the percentage (0 to 100%) of nuclei sampled staining at each of these intensity levels was determined. A total intensity score (0 to 300) was the summation of the products of each intensity score (0 to 3) and their corresponding percentages. Cancer sections (166 +/- 69) stained less intensely and more heterogeneously than BPH in cancer patients (246 +/- 41, Student's t test p < 0.05) and noncancer patients (225 +/- 39, p < 0.05). The decreased intensity and greater heterogeneity of androgen receptor staining in cancer tissue may implicate a quantitative or functional difference in androgen receptor between prostatic carcinoma and BPH.